Newsroom | 48214 results

WALTHAM, Mass. & KYOTO, Japan--(BUSINESS WIRE)--（ビジネスワイヤ） -- AI技術を活用した分子・免疫プロファイリングにより、医薬品開発と患者個別化医療を支援する先進的企業であるBostonGene、医学と科学の分野において最先端の研究機関である京都大学は、食道扁平上皮がん患者に対する複合がん免疫療法に関するバイオマーカー探索を目的とする共同研究を実施することに合意しました。 本共同研究は、京都大学の武藤学教授が主導する医師主導試験であるNOBEL試験で得られた患者検体を用いる研究であり、BostonGeneが有するAI技術を活用し、食道扁平上皮がん患者のゲノムプロファイリングとトランスクリプトームプロファイリングを統合させ、複合がん免疫療法に対するより適切な患者層別化を可能にするバイオマーカーを探索します。 本研究の一環として、京都大学は臨床サンプルと患者データを提供し、BostonGeneはAIを活用した分子プロファイリングと、治療レスポンスに影響を与える重要なバイオマーカーを特定します。 BostonGene Japan株式会社代...

加州愛莫利維爾--(BUSINESS WIRE)--(美國商業資訊)-- (美國商業資訊)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA)（簡稱「Estrella」或「公司」）是一家臨床階段生物製藥公司，致力於開發標靶作用於CD19和CD22的ARTEMIS® T細胞療法以治療癌症和自身免疫性疾病。公司今日宣布，其用於治療晚期B細胞非霍奇金淋巴瘤（NHL）的CD19標靶ARTEMIS® T細胞療法EB103已經順利完成STARLIGHT-1第I/II期臨床試驗的第I期劑量爬坡階段的第二劑量組。 關鍵發現： 在該研究第二劑量組中，所有可評估病患在治療第1個月時均達到完全緩解（CR），完全緩解率為100%。 所有接受治療的病患均為不適合接受商業化CD19產品治療的高風險人群，其中包括一名中樞神經系統（CNS）淋巴瘤病患。在本研究階段，未發生任何與治療相關的嚴重不良事件（SAE）。 Estrella執行長劉誠博士表示：「第二劑量組以100%的完全緩解率完成，這是我們EB103臨床專案中的一個重要里程碑。在這一高風險受試群體（包括一名中樞神經系統淋巴瘤...

ROCHESTER, Minn.--(BUSINESS WIRE)--Please replace the release with the following corrected version due to multiple revisions. The updated release reads: RION LAUNCHES RION VET TO TRANSFORM ANIMAL HEALTH WITH FIRST-IN-CLASS BIOLOGIC THERAPEUTIC; APPOINTS INDUSTRY LEADER MARK HERTHEL AS CEO; ANNOUNCES SERIES A FULFILLMENT RION, a clinical-stage regenerative medicine company and global leader in exosome-based therapeutics, today announced the formation of RION Vet, a veterinary biotechnology compa...

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it intends to offer, subject to market conditions and other factors, $700.0 million aggregate principal amount of Convertible Senior Notes due 2030 (the “notes”) in a private placement (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Ionis also intends to grant the initial purchasers of the notes an option...

WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, today announced that Mary Szela, Chief Executive Officer and President, and David Patience, Chief Financial Officer, will participate in the following investor conferences in November: Canaccord Genuity MedTech, Diagnostics and Digital Health...

WATERTOWN, Mass. & STEVENAGE, England--(BUSINESS WIRE)--Dyno Therapeutics and Trisk Bio announce strategic manufacturing partnership through expanded Frontiers Program...

WATERTOWN, Mass.--(BUSINESS WIRE)--Dyno Therapeutics unveils best-in-class Dyno-bn8 AAV vector for muscle gene therapies, achieving therapeutic delivery with improved safety potential...

LAGUNA HILLS, Calif. & HOUSTON--(BUSINESS WIRE)--Medley Therapeutics, Inc. (formerly YAP Therapeutics), a company developing regenerative genetic medicines and advanced biologics, today announced completion of dosing in the first cohort (n=3) of the Phase 1 SALVADOR-HF clinical trial evaluating YAP101 in patients with advanced ischemic heart failure with reduced ejection fraction (HFrEF) at The Texas Heart Institute at Baylor College of Medicine and at the St. Luke’s Medical Center (Houston). F...

HAMBURG, Germany--(BUSINESS WIRE)--acCELLerate, a manufacturer of assay-ready frozen cells has established an agreement with ATCC a global biological resource and standards organization. Under the agreement, acCELLerate will produce custom cell banks from ATCC cell lines for research clients in the pharmaceutical and biotechnology industry. This collaboration combines ATCC’s internationally recognized portfolio of high-quality, authenticated cell lines with acCELLerate’s expertise in cryopreser...

DUBLIN--(BUSINESS WIRE)--Phase 2 clinical data for coramitug, a potential first-in-class amyloid depleter antibody, for the treatment of ATTR-CM published in Circulation....